Shire plc : Director/PDMR Shareholding

Director/PDMR Shareholding
August 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transaction by person discharging managerial responsibilities
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a)NameFlemming Ornskov
2. Reason for the notification
a)Position / statusChief Executive Officer - PDMR
b)Initial notification / amendmentInitial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")

Identification codeISIN: JE00B2QKY057
b)Nature of the transactionAcquisition of Ordinary Shares
c)Price(s) and volume(s)Price(s)Volume(s)
d) Aggregated information

- Aggregated volume

- Price
N/A (single transaction)
e)Date of the transactionAugust 22, 2017
f)Place of the transactionLondon Stock Exchange


Oliver Strawbridge

Senior Assistant Company Secretary

For further information please contact:


Investor Relations   
Ian Karp +1 781 482 9018
Robert Coates +44 1256 894874
Lisa 617 588 8607
Debbi Ford   +1 617 949 9083




About Shire


Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.


Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Shire plc via GlobeNewswire